Kodiak Sciences (KOD) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
16 Nov, 2026Pipeline and DAYBREAK results
Retina-focused pipeline includes three late-stage assets: tarcocimab (Zenkuda), KSI-101 and KSI-501.
GLOW2 reported strong, safe-looking Phase III results in diabetic retinopathy in March, using the commercial formulation.
In DAYBREAK, Zenkuda showed rapid effect versus EYLEA and sustained vision gains; more than half of patients reached six-month dosing under sensitive retreatment criteria.
48% reached six-month dosing after loading; six months was the protocol cap, and management said more than half did not meet retreatment criteria at the cap.
Management said patient durability varies substantially; year-two intervals may shorten for some patients and lengthen for others.
Zenkuda filing and commercialization
A multi-indication BLA for wet AMD, retinal vein occlusion and diabetic retinopathy was targeted before year-end 2026; management said the filing was on track and FDA had agreed to the combined filing and formulation bridge.
Management described remaining BLA work as assembly and filing, with no fundamental unknowns.
The hoped-for label would be straightforward and reflect the commercial formulation; management advocated flexible dosing, potentially Q4–Q24 in wet AMD and a broad interval range in RVO and DR.
Management positioned Zenkuda as a potential option across patients, aiming to extend existing dosing intervals while retaining rapid effect; market share and pricing remained uncertain.
Approval was projected by year-end 2027, subject to regulatory review.
KSI-101 and MESI program
KSI-101 targets inflammatory macular edema (MESI); PEAK 1 was fully enrolled, with top-line results expected before Christmas 2026, and the pivotal program also includes PEAK 2 and PINNACLE.
PEAK 2 and PINNACLE top-line data were anticipated in May–June 2027; a filing could follow PEAK 1 alone as early as April, or use PEAK 1 safety data plus the other studies’ primary endpoints around mid-2027.
Management described the MESI population as broad, including severely affected, uveitic and refractory postsurgical patients, and said the label population should reflect those studied.
KSI-101’s pivotal studies compare against sham; approval was projected for early 2028.
Latest events from Kodiak Sciences
- Tarcocimab advances toward filing as KSI-101’s pivotal data approach.KOD
UBS Global Biopharma Conference 2026 - DAYBREAK advanced two programs, but losses and financing risks persist.KOD
Q3 2026 - Both drugs matched aflibercept efficacy, enabling 6-month dosing for most patients.KOD
Study result - Net loss hit $123.8M in H1 2026; cash supports operations into 2027, but funding gap remains.KOD
Q2 2026 - Late-stage retinal therapies advance toward key data and BLA filings, targeting approvals by 2027.KOD
Jefferies Global Healthcare Conference 2026 - Q1 2026 saw a $58.2M net loss, strong Phase 3 data, and pivotal trials with funding needs ahead.KOD
Q1 2026 - Virtual meeting to elect directors, approve pay, and ratify auditor, with board support.KOD
Proxy filing - Shareholders will vote on directors, executive pay, and auditor, with a focus on performance and ESG.KOD
Proxy filing - Pivotal retinal trials advance with improved formulations and strong financial runway.KOD
Goldman Sachs 45th Annual Global Healthcare Conference